
2019 Postgraduate Course: Precision Hepatology in Clinical Practice
Recorded On: 11/09/2019
DESCRIPTION
The practice of Hepatology is largely consultative in nature, whether evaluating outpatients referred for a variety of abnormal liver enzyme findings or diagnosing and managing critically-ill patients within a team of internists, hospitalists, residents, intensivists, and other healthcare providers. On any given day, a hepatologist will be confronted with complex patients and dizzying differential diagnoses to be methodically considered. The aim of this course is to provide insights about state-of-the-art consultative Hepatology attendees that can be applied to daily practice.
CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 7.00 AMA PRA Category 1 Credits™
Maintenance of Certification (MOC): For a maximum of 7.00 MOC Points
COMPONENTS
Online presentations comprised of PowerPoint slides and accompanying audio with an assessment to complete at the end.
-Five sessions comprised of three to five video presentations for 15-20 minutes each
-Course assessment (quiz)
-Course evaluation to claim continuing education credit
DIRECTIONS
Click "Activate/Register" to access the enduring material. Review all section tabs before you begin. Begin video presentations in all sessions. Complete course assessment and evaluation to claim CME and or MOC.
Time to complete each module: 15-20 minutes
COPYRIGHT
All faculty in this activity have given their permission for publication ©2020 AASLD.
CONTACT INFORMATION
For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org.
Release date: January 9, 2020
Expiration date: January 8, 2023
Upon completion of this activity, participants will be able to:
Review evidence-based evaluation and management options available for a spectrum of liver diseases, their benefits and risks, and strategies to tailor treatment plans to individual patients.
Discuss the value of circulating and tissue biomarkers in making rational decisions for optimal patient care.
Apply information on minimally invasive tests and digital tools to identify biomarkers to the clinical practice of hepatology.
Hepatologists
Gastroenterologists
Nurses
Nurse Practitioners
Pharmacists
Physician Assistants
Transplant Coordinators
Surgeons
Fellows/Trainees
CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 7.00 AMA PRA Category 1 Credits™
Maintenance of Certification (MOC): For a maximum of 7.00 MOC Points
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 7 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
HOW TO EARN AND CLAIM MOC POINTS
o View all video presentation in each session.
o Complete the course evaluation.
o Complete the CME and MOC assessment. You must pass with a score of 70% or higher. Participants have unlimited attempts to earn the passing score.
o Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)
MOC completions are collected on the 15th of each month and submitted to ABIM and ABP by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM or ABP MOC profile.
**MOC points are available for ABIM or ABP board certified physicians only.**
Robert Fontana, MD, FAASLD
Kathryn Fowler, MD
Scott Friedman, MD, FAASLD
Fasiha Kanwal, MD, MSHS, FAASLD
Tom H. Karlsen, MD, PhD
Verena Keitel, Prof.
Laura Kulik, MD
Jennifer C. Lai, MD
Konstantinos Lazaridis, MD, FAASLD
Joseph Llovet, MD
Michael Lucey, MD, FAASLD
Cara Mack, MD, FAASLD
Alexander Miethke, MD
Tushar Patel, MBCHb, FAASLD
Mary Rinella, MD, FAASLD
Don Rockey, MD, FAASLD
Bernd Schnabl, MD, FAASLD
Gyongyi Szabo, MD, PhD, FAASLD
Norah Terrault, MD, MPH, FAASLD
Michael Trauner, MD, FAASLD
Kymberly Watt, MD
DISCLOSURE OF CONFLICTS OF INTEREST
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
This enduring activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the AASLD Postgraduate Course faculty and the following planning committees: Education Committee, Scientific Program Committee and the Governing Board.
As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.
Statement on off-label and investigational use: Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. Financial disclosures will appear at the beginning of each session and are provided below:
FACULTY DISCLOSURES
Meena Bansal
AASLD Postgraduate Course Faculty
Nothing to Disclose
Ulrich Beuers
AASLD Postgraduate Course Faculty
Grant/Research Support: Intercept, Dr.Falk GmbH
Speaking and Teaching: Intercept, Falk Foundation
Jorge Bezerra
AASLD Postgraduate Course Faculty
Nothing to Disclose
Raymond Chung
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: Alnylam
Grant/Research Support: Boehringer, BMS, Merck, Gilead, Abbvie, Janssen, Roche, Synlogic, Kaleido
Robert Fontana
AASLD Postgraduate Course Faculty
Consulting: Sanofi
Grant/Research Support: BMS, Gilead, Abbvie
Kathryn Fowler
AASLD Postgraduate Course Faculty
Consulting: 12 Sigma
Scott Friedman
AASLD Postgraduate Course Faculty
Consulting: 3BV Bio, 89Bio, Abide Thearapeutics, Allergan Pharmaceuticals, Avaliv Therapeutics, Axcella Therapeutics, Blade Therapeutics, Bristol Myers Squibb, Contravir, CymaBay, DeuteRx, Enanta Pharmaceuticals, Escient Therapeutics, Exalenz Biosciences, Forbion, Fractyl Bioscience, Five Prime Therapeutics , Galmed, Genfit, Gemphire, Glycotest, Heparegenix, Janssen Pharmaceuticals, Jecure Therapeutics, Kintai, Madrigal Pharmaceuticals, Metacrine, Mistral, Morphic Rock Therapeutics, NGM Pharmaceuticals, Nimbus Therapeutics, Nitto Corp., North Sea Therapeutics, Novartis, Novo Nordisk, Pfizer Pharmaceuticals, Salix, Scholar Rock, Seal Rock Therapeutics, Second Genome, Surrozen, Symbic Bio, Takeda Pharmaceuticals, Viking Therapeutics
Grant/Research Support: 3VBio, Enanta, Scholar Rock, Gemphire, North Sea Therapeutics
Fasiha Kanwal
AASLD Postgraduate Course Faculty
Grant/Research Support: Merck, Gilead
Tom Karlsen
AASLD Postgraduate Course Faculty
Nothing to Disclose
Andrew Keaveny
AASLD Postgraduate Course Faculty
Grant/Research Support: HepQuant LLC, Conatus Pharmaceuticals, Mallinckrodt Medical Inc
Independent Contractor: UpToDate Inc
Speaking and Teaching: Medscape Inc.
Verena Keitel
AASLD Postgraduate Course Faculty
Speaking and Teaching: Abbvie, Falk Foundation
Laura Kulik
AASLD Postgraduate Course Faculty
Nothing to Disclose
Jennifer C. Lai
AASLD Postgraduate Course Faculty
Consulting: Axcella Health, Inc
Konstantinos Lazaridis
AASLD Postgraduate Course Faculty
Nothing to Disclose
Josep Llovet
AASLD Postgraduate Course Faculty
Consulting: Ipsen, Merck, Bristol Myers Squibb, Eisai Inc, Bayer HealthCare Pharmaceuticals, Midatech Ltd, Navigant, Fortress Biotech Inc, Spring Bank Pharmaceutical, Glycotest, Leerink Swann LLC, Eli Lilly, Celsion Corporation, Exelixis, Nucleix, Can-Fite Biopharma
Grant/Research Support: Bristol Myers Squibb, Eisai Inc, Bayer Healthcare Pharmaceuticals, Ipsen, Blueprint Incyte
Rohit Loomba
AASLD Postgraduate Course Faculty
Consulting: Bird Rock Bio, Merck & Co., NGM, Cymabay, Metacrine, Ionis, Glympse Bio, Pfizer, Eli Lilly and Company
Grant/Research Support: Intercept, NGM Bio, Novo Nordisk, Novartis, Prometheus, Janssen, Cirius Therapeutics, Gilead, Eli Lilly
Michael Lucey
AASLD Postgraduate Course Faculty
Grant/Research Support: NIAAA, Pharma-solutions, Gilead, Abbvie
Cara Mack
AASLD Postgraduate Course Faculty
Consulting: albireo
Alexander Miethke
AASLD Postgraduate Course Faculty
Consulting: Mirum Inc, Metacrine Inc
Lopa Mishra
Research Grants: NIH
Vicky Ng
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: Albireo
Tushar Patel
AASLD Postgraduate Course Faculty
Disclosures were not provided
Nancy Reau
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: Gilead, intercept, Merck, abbVie
Consulting: BMS
Grant/Research Support: GenFit
Mary Rinella
AASLD Postgraduate Course Faculty
Consulting: NGM Biopharmaceuticals, Genfit, Gilead, Intercept, Novartis, Metacrine, Bristol Meyers Squibb, Gelesis, Fractyl, Pfizer, Madrigal, Enanta, Echosens, Merck, Viking
Grant/Research Support: Gilead, Conatus, NGM, Cirius, Enanta, Intercept, Novartis, Allergan
Don Rockey
AASLD Postgraduate Course Faculty
Grant/Research Support: Terlipressin, Intercept Pharm, Mallinckrodt Pharm, Genfit Reg, INC, Aflmmune, Salix, Cumberland Pharm, NIH/NIDDK, Ironwood Pharm, Gilead Services, Conatus Pharm
Bernd Schnabl
AASLD Postgraduate Course Faculty
Consulting: Ferring Pharmaceuticals, Patara Pharmaceuticals, Intercept Pharmaceuticals
Grant/Research Support: CymaBay Therapeutics, Synlogic Operating Company
Ronald Sokol
AASLD Postgraduate Course Faculty
Consulting: Alexion, Retrophin, Shire, Albireo
Gyongyi Szabo
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: UPENN Digestive Disease Center, Yale Liver Center, BWH-DSMB, VCU MSTP, NIH ExRNA Program, UCLA Liver Center, Galaxy Project, Nature Gastro & Hepatology, University of Pittsburgh MSTP Program, University of Louisville Alcohol Center, Upstate Medical Univ. Syracuse NY, Carlos Foundation- Mayo Clinic, MICA
Norah Terrault
AASLD Postgraduate Course Faculty
Grant/Research Support: Gilead Sciences
Michael Trauner
AASLD Postgraduate Course Faculty
Consulting: Albireo, BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, Regulus
Grant/Research Support: Albireo, Cymabay, Falk, Gilead, Intercept, MSD, Takeda
Speaking and Teaching: Falk, Gilead, Intercept, MSD, Roche
Kymberly Watt
AASLD Postgraduate Course Faculty
Stock Shareholder: Arbutus, Madrigal, Viking, BMS
Rebecca Wells
AASLD Postgraduate Course Faculty
Nothing to Disclose
PLANNER DISCLOSURES
Veeral Ajmera
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Luminist Incorporated
Gyorgy Baffy
Annual Meeting Education Committee
Nothing to Disclose
Meena Bansal
Governing Board and Scientific Program Committee
Data Safety Monitoring Board for Industry or Commercial Enterprise: TREAT Consortium (NIH; not commercial entity)
Research Grants: Paid to institution: NIH R01
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Kinetix Group; Boehringer-Ingelheim
Ramon Bataller
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Echosens
Alex Befeler
Scientific Program Committee
Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: Amgen
long term stockholder (independently managed by CPA), Gilead long term stockholder (independently managed by CPA)
Research Grants: mallinckrodt, Salix, Sillajen
Jorge Bezerra
Governing Board and Scientific Program Committee
Research Grants: Gilead; Shyer
Andres Cardenas
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Boston Scientific Corp Scientific
Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Mallinckrodt Pharmaceuticals - Consultant
Raymond Chung
Governing Board and Scientific Program Committee
Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB Alnylam
Research Grants: Gilead Sciences. Abbvie, Boehringer Ingelheim, BMS, Roche, Janssen, Merck, Kaleido, Synlogic
Virginia Clark
Annual Meeting Education Committee
Research Grants: Genfit
James Daniel
Annual Meeting Education Committee
Research Grants: Gilead and Hoffmann- La Roche
Laurie DeLeve
Annual Meeting Education Committee and Governing Board
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Abbvie, Pfizer, Daiichi Sankyo, Boehringer-Ingelheim
Intellectual Property Rights (Patents, Royalties, Licensing fees): 2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment, COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES -(sole inventor) - Applicant: University of Southern California, GBC ref.: 6177.132445PCT
Michael Fried
Governing Board and Scientific Program Committee
Research Grants: AbbVie, BMS, Gilead, Merck, National Institutes of Health
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated) Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: TARGET PharmaSolutions (Maintained in independent blind trust)
Patrick Horne
Annual Meeting Education Committee and Scientific Program Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Abbvie, Gilead, Intercept
Sofia Jakab
Annual Meeting Education Committee
Nothing to Disclose
Michael Kriss
Annual Meeting Education Committee
Nothing to Disclose
Laura Kulik
Annual Meeting Education Committee
Nothing to Disclose
John Lake
Governing Board
Research Grants: CymbaBay, Data Safety
Monitoring Board for Industry or Commercial Enterprise: Intercept DSMB
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: SRTR
Bruce Luxon
Governing Board
Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB for Baxalta; DSMB for Sparks (for treatment of Hemophilia)
Leadership in related society: Board, Committee, Journal: Research Committee member for the ACG
John Magee
Scientific Program Committee
Nothing to Disclose
Mitchell Mah'moud
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Chronic Liver a Disease Foundation
Harmeet Malhi
Scientific Program Committee
Research Grants: NIH R01 NIH U01
Lopa Mishra
Governing Board
Research Grants: NIH
David Mulligan
Governing Board
Nothing to Disclose
Mary Panther
Annual Meeting Education Committee
Nothing to Disclose
K. Gautham Reddy
Scientific Program Committee
Research Grants: CymaBay; Genfit; Intercept; Target PharmaSolutions; Arrowhead; Gilead; Durect;
Commercial Speaker's Bureau: Intercept, Dova
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept
Hemant Shah
Annual Meeting Education Committee
Advisory Board: Abbvie, Gilead, Intercept, Lupin, Merck, Pendopharm
Ronald Sokol
Governing Board
Research Grants: Paid to institution: Lumena/Shire; Albireo
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Alexion; Albireo; Retrophin; Shire; Mirum
Richard Sterling
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Gilead, Roche, AbbVie, Baxter, Pfizer, Merck within the last 12 months.
I have had no activity with Gilead, AbbVie, and Merck in the last 6 months in anticipation of the Non-Invasive Guidelines paper that is expected to start 2018.
Research Grants: Gilead, Roche, True Health, AbbVie, Abbott
Grace Su
Annual Meeting Education Committee and Scientific Program Committee
Intellectual Property Rights (Patents, Royalties, Licensing fees): Patent on Image analysis and Morphomic
Leadership in related society: Board, Committee Journal: Member, Clinical Guidelines Committee, AGA; Company Employee, Officer, Director : My husband and son have equity interest in Applied Morphomics and Prenovo.
Norah Terrault
Governing Board
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Advisory Committees or Review Panels: Dova Pharmaceuticals
Research Grants: Grant/Research Support: AbbVie, Gilead, BMS, Merck
Jason Vanatta
Annual Meeting Education Committee
Nothing to Disclose
Kymberly Watt
Scientific Program Committee
Expert testimony: Intercept - site- PI
Gilead - site PI, co-I
Conatus - site co-I
Novartis - previous site PI, co author study subanalysis
Pfizer- site co-I (all multicenter study related)
Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: BMS; Arbutus; Madrigal; Viking
Steven Weinman
Annual Meeting Education Committee
Nothing to Disclose
Maureen Whitsett
Annual Meeting Education Committee
Nothing to Disclose
AASLD STAFF DISCLOSURES
Greg Bologna
AASLD Staff
Nothing to Disclose
Dominique Clayton
AASLD Staff
Nothing to Disclose
Amy D'Amato
AASLD Staff
Nothing to Disclose
Julie Deal
AASLD Staff
Nothing to Disclose
Katie Duggan
AASLD Staff
Nothing to Disclose
Stephanie Graham
AASLD Staff
Nothing to Disclose
Stephanie Grimsby
AASLD Staff
Nothing to Disclose
Jessica Jessop
AASLD Staff
Nothing to Disclose
Janeil C. Klett
AASLD Staff
Nothing to Disclose
John Lingerfelt
AASLD Staff
Nothing to Disclose
Julia Merrill
AASLD Staff
Nothing to Disclose
Bette Anne Preston
AASLD Staff
Nothing to Disclose
Diane Perrino
AASLD Staff
Nothing to disclose
Denise Seise
AASLD Staff
Nothing to disclose
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.
Key:




